A5054388769- HIV/AIDS Research and Interventions
- HIV Research and Treatment
- HIV/AIDS drug development and treatment
- HIV/AIDS Impact and Responses
- Global Maternal and Child Health
- HIV, Drug Use, Sexual Risk
- Pneumocystis jirovecii pneumonia detection and treatment
- Tuberculosis Research and Epidemiology
- Adolescent Sexual and Reproductive Health
- Reproductive Health and Contraception
- Poverty, Education, and Child Welfare
- Global Healthcare and Medical Tourism
- Global Health and Epidemiology
- Bartonella species infections research
- Child and Adolescent Health
- Data-Driven Disease Surveillance
- Pharmacological Effects and Toxicity Studies
- Antifungal resistance and susceptibility
- IL-33, ST2, and ILC Pathways
- ICT in Developing Communities
- HIV/AIDS oral health manifestations
- Animal Virus Infections Studies
- Adolescent and Pediatric Healthcare
- Sexual function and dysfunction studies
- Eosinophilic Disorders and Syndromes
Botswana Harvard AIDS Institute Partnership
2004-2024
Ministry of Health
2008-2019
Harvard University
2005-2008
Antiretroviral treatment (ART) initiatives have now been established in many sub-Saharan African countries showing early benefits. To date, few results are available concerning long-term clinical outcomes these programs.Response to ART is described the first HIV-1C-infected adults enrolled Botswana Treatment Program 2002. Data analysis was conducted on longitudinal data up 1st April 2007.Six hundred thirty-three severely immunodeficient patients with a median CD4+ cell count of 67...
Background: Dolutegravir (DTG)-based antiretroviral therapy (ART) rarely leads to virological failure (VF) and drug resistance in integrase strand transfer inhibitor (INSTI)-naïve persons living with HIV (PLWH). As a result, limited data are available on INSTI-associated mutations (DRMs) selected by DTG-containing ART regimens. Methods: We reviewed studies published through July 2023 identify those reporting emergent major DRMs INSTI-naïve PLWH receiving DTG containing vitro susceptibility...
Background: Dolutegravir (DTG) is a cornerstone of global antiretroviral (ARV) therapy (ART) due to its high efficacy and favorable tolerability. However, limited data exist regarding the risk emergent integrase strand transfer inhibitor (INSTI) drug-resistance mutations (DRMs) in individuals receiving DTG-containing ART. Methods: We performed PubMed search using term “Dolutegravir”, last updated 18 December 2023, estimate prevalence VF with INSTI DRMs people living HIV (PLWH) without...
To describe the response to highly active antiretroviral treatment (HAART) in a public sector pilot (ARV) program Botswana.The HAART is described adult HIV-infected ARV-naive patients initiating from April 2001 January 2002 at Princess Marina Hospital Gaborone, Botswana. Patients had medical and laboratory evaluations before ARV were followed longitudinally. For analysis, data collected charts patient management records.One hundred fifty-three initiated HAART. Most received didanosine plus...
BackgroundMonitoring the effectiveness of global antiretroviral therapy scale-up efforts in resource-limited settings is a health priority, but complicated by high rates losses to follow-up after treatment initiation. Determining definitive outcomes these lost patients, and effects on estimates survival risk factors for death HAART, are key monitoring HAART efforts.Methodology/Principal FindingsA cohort study comparing clinical initiation as reported before tracing patients was conducted...
We analyzed the reverse transcriptase genotypes of human immunodeficiency virus type 1 subtype C viruses isolated from 23 patients in Botswana treated with didanosine-based regimens. The K65R mutation was selected either alone or together Q151M, S68G, F116Y substitution seven such individuals. results vitro passage experiments were consistent an apparent increased propensity to develop substitution.
ABSTRACT Background Dolutegravir (DTG) is a cornerstone of global antiretroviral (ARV) therapy (ART) due to its high efficacy and favorable tolerability. However, limited data exist regarding the risk virological failure (VF) with emergent integrase strand transfer inhibitor (INSTI) drug-resistance mutations (DRMs) in individuals receiving DTG-containing ART. Methods We performed PubMed search using term “Dolutegravir” last updated December 18, 2023, estimate prevalence VF INSTI DRMs...
In industrialized countries, it is recommended that adults with human immunodeficiency virus type 1 (HIV-1) infection undergo baseline screening for pathogens might cause latent or active infections, such as syphilis, hepatitis B, C, due to Toxoplasma gondii, and cytomegalovirus infection. A paucity of data exist from sub-Saharan Africa describing the prevalence these pathogens. We report HIV-1-infected referred initiation highly antiretroviral therapy in Botswana.
Abstract Little is published about the disclosure of parents' own HIV status to their children in Africa. Research shows that keeping family secrets from children, including those related a parent's status, can be detrimental psychological well-being and structure family. Further, with HIV-positive parents have been shown more vulnerable poorer reproductive health outcomes. This qualitative study Botswana conducted in-depth interviews among 21 on antiretroviral therapy. The data revealed...
There are limited data on the effectiveness of dolutegravir (DTG)-based combination antiretroviral therapy (ART) in real-life settings southern Africa where HIV-1 subtype C predominates. We report a patient infected with DTG-based ART previously exposed to raltegravir who developed multidrug resistance mutations four classes. is need for drug monitoring and clinical vigilance ensure HIV treatment programs even era ART.
Countries in sub-Saharan Africa are under significant pressure to open large-scale, public antiretroviral treatment clinics. Many lessons have been learned Botswana, where the first clinic was established. The availability of core, well-trained medical staff will be primary factor that limits a rapid scale-up programs.
Among 16 human immunodeficiency virus-infected (subtype C) Batswana patients who failed nelfinavir (NFV)-containing regimens, the most prevalent mutation observed was D30N (54%), followed by L90M (31%). L89I, K20T/I, and E35D polymorphic changes were also identified. These findings suggest that subtype C viruses in Botswana may develop resistance to NFV via subtype-specific pathways.
In parallel with the rollout of Botswana's national antiretroviral therapy (ART) program, Botswana Ministry Health established KITSO AIDS Training Program by entering into long-term partnerships Botswana-Harvard Institute Partnership for HIV Research and Education others to provide standardized, country-specific training in HIV/AIDS care. The model has strengthened human capacity within health sector been indispensable successful ART rollout. Through core advanced courses clinical mentoring,...
To detect and characterize polymerase gene ( pol) polymorphisms mutation patterns in HIV-1C-infected Batswana patients treated with reverse transcriptase inhibitors, samples from AIDS highly active antiretroviral therapy (HAART) were sequenced for the region encompassing entire HIV-1 protease (PR) first 335 amino acids of (RT). Amongst 16 (ARV) drugs, eight started HAART regimens containing didanosine, stavudine nevirapine (ddI/d4T/NVP) or efavirenz (EFV) (arm A) while others zidovudine...
Cryptococcal meningitis (CM) causes substantial mortality in African countries with a high prevalence of human immunodeficiency virus (HIV), despite advances disease management and increasing antiretroviral therapy (ART) coverage. Reliable diagnosis CM is cheap more accessible than other indicators advanced HIV burden such as CD4 testing or investigation for disseminated tuberculosis; therefore, monitoring incidence has the potential to serve valuable metric programmatic success. Botswana...
Background Roll-out of Integrase Strand Transfer Inhibitors (INSTIs) such as dolutegravir for HIV combination antiretroviral therapy (cART) in sub-Saharan Africa necessitates the development affordable drug resistance (HIVDR) assays targeting gene. We optimised and evaluated an in-house integrase HIV-1 assay (IH-Int) compared it to a commercially available assay, ViroSeq™ Genotyping kit (VS-Int) amongst clade C infected individuals. Methods used 54 plasma samples from treatment naïve...
Individual patient care and programme evaluation are pivotal for the success of antiretroviral treatment programmes in resource-limited countries. While computer-aided documentation data storage indispensable any large programme, several important issues need to be addressed including which collected, who collects it how is entered into an electronic database. We describe a patient-monitoring approach, uses encounter forms (in hybrid paper + format) based on optical character recognition,...